Bank of America Corp DE Lowers Position in Dynavax Technologies Co. (NASDAQ:DVAX)

Bank of America Corp DE cut its stake in Dynavax Technologies Co. (NASDAQ:DVAX - Free Report) by 15.1% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 699,026 shares of the biopharmaceutical company's stock after selling 124,301 shares during the period. Bank of America Corp DE owned approximately 0.53% of Dynavax Technologies worth $8,927,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Barclays PLC increased its stake in Dynavax Technologies by 137.4% in the 3rd quarter. Barclays PLC now owns 302,572 shares of the biopharmaceutical company's stock valued at $3,371,000 after purchasing an additional 175,118 shares in the last quarter. Ballentine Partners LLC purchased a new position in shares of Dynavax Technologies in the fourth quarter valued at $137,000. Nisa Investment Advisors LLC raised its stake in shares of Dynavax Technologies by 19.8% during the 4th quarter. Nisa Investment Advisors LLC now owns 6,517 shares of the biopharmaceutical company's stock worth $83,000 after buying an additional 1,076 shares during the last quarter. SG Americas Securities LLC purchased a new stake in shares of Dynavax Technologies in the 4th quarter worth about $990,000. Finally, Exchange Traded Concepts LLC boosted its position in shares of Dynavax Technologies by 4.3% in the 4th quarter. Exchange Traded Concepts LLC now owns 162,726 shares of the biopharmaceutical company's stock worth $2,078,000 after buying an additional 6,712 shares in the last quarter. 96.96% of the stock is currently owned by institutional investors and hedge funds.

Dynavax Technologies Trading Up 2.4%

Shares of DVAX traded up $0.23 on Thursday, hitting $9.73. 505,977 shares of the stock traded hands, compared to its average volume of 2,209,532. Dynavax Technologies Co. has a 1 year low of $9.22 and a 1 year high of $14.63. The stock's 50 day moving average is $11.16 and its two-hundred day moving average is $12.38. The firm has a market capitalization of $1.17 billion, a P/E ratio of 54.03 and a beta of 1.26. The company has a quick ratio of 12.34, a current ratio of 13.23 and a debt-to-equity ratio of 0.33.

Dynavax Technologies (NASDAQ:DVAX - Get Free Report) last posted its quarterly earnings data on Tuesday, May 6th. The biopharmaceutical company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.03 by ($0.14). The business had revenue of $68.16 million for the quarter, compared to analyst estimates of $70.01 million. Dynavax Technologies had a return on equity of 4.22% and a net margin of 9.85%. As a group, sell-side analysts predict that Dynavax Technologies Co. will post 0.32 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on DVAX. JMP Securities cut their target price on shares of Dynavax Technologies from $33.00 to $31.00 and set a "market outperform" rating for the company in a research report on Wednesday, May 7th. William Blair restated an "outperform" rating on shares of Dynavax Technologies in a research report on Friday, February 21st. The Goldman Sachs Group lowered their target price on Dynavax Technologies from $12.00 to $10.00 and set a "sell" rating on the stock in a report on Thursday, April 17th. Wall Street Zen cut Dynavax Technologies from a "buy" rating to a "hold" rating in a report on Tuesday, May 6th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $31.00 price objective on shares of Dynavax Technologies in a research note on Friday, February 21st. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of "Hold" and a consensus price target of $24.00.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.